Edition:
India

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.79USD
17 May 2019
Change (% chg)

$0.03 (+0.80%)
Prev Close
$3.76
Open
$3.76
Day's High
$3.84
Day's Low
$3.68
Volume
498,038
Avg. Vol
437,253
52-wk High
$6.16
52-wk Low
$1.85

Select another date:

Fri, Mar 1 2019

UPDATE 1-U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

Feb 28 U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

UPDATE 3-Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Feb 21 Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Catalyst defends drug price after Bernie Sanders' rebuke

Feb 21 Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

UPDATE 1-U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

Select another date: